Respiratory syncytial virus vaccine nanopatch - Vaxxas
Alternative Names: HD-MAP/RSVLatest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator National Institutes of Health
- Developer National Institutes of Health; Vaxxas
- Class Antiseptics; Antivirals; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections